Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026)
Surrozen (SRZN) posted quarterly Total Non-Current Liabilities of $163.3 million for Q1 2026, up 144.77% year-over-year from $66.7 million in Q1 2025, and up 27.78% quarter-over-quarter from $127.8 million in Q4 2025.
Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Surrozen's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $163.3 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 144.77% year-over-year to $163.3 million; the TTM figure through Mar 2026 stood at $163.3 million (up 144.77% YoY), while the FY2025 annual figure was $127.8 million, up 815.99% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $163.3 million, up from $127.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $163.3 million in Q1 2026, with the low at $6.0 million in Q2 2024.
- The 5-year median for Total Non-Current Liabilities is $13.0 million (2022), against an average of $33.2 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities sank 39.44% in 2024, then jumped 946.03% in 2025.
- Surrozen's Total Non-Current Liabilities stood at $13.1 million in 2022, then slumped by 38.74% to $8.0 million in 2023, then jumped by 73.79% to $14.0 million in 2024, then surged by 815.99% to $127.8 million in 2025, then grew by 27.78% to $163.3 million in 2026.
- Business Quant data shows SRZN's Total Non-Current Liabilities at $163.3 million in Q1 2026, $127.8 million in Q4 2025, and $64.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 138.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 138.00 Mn |
| Mar 31, 2026 | 163.34 Mn |
| Dec 31, 2025 | 127.83 Mn |
| Sep 30, 2025 | 64.02 Mn |
| Jun 30, 2025 | 22.96 Mn |
| Mar 31, 2025 | 66.73 Mn |
| Dec 31, 2024 | 13.96 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 6.40 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 8.62 Mn |
| Mar 31, 2023 | 10.57 Mn |
| Dec 31, 2022 | 13.11 Mn |
| Sep 30, 2022 | 12.61 Mn |
| Jun 30, 2022 | 13.05 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 19.17 Mn |
| Sep 30, 2021 | 18.60 Mn |